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Whereas estrogen–estrogen receptor  (ER) signaling
plays an important role in breast cancer growth, it
is also necessary for the differentiation of normal
breast epithelial cells. How this functional conver-
sion occurs, however, remains unknown. Based on
a genome-wide sequencing study that identified mu-
tations in several breast cancer genes, we examined
some of the genes for mutations, expression levels,
and functional effects on cell proliferation and tumor-
igenesis. We present the data for C1orf64 or ER-re-
lated factor (ERRF) from 31 cell lines and 367 primary
breast cancer tumors. Whereas mutation of ERRF was
infrequent (1 of 79 or 1.3%), its expression was up-
regulated in breast cancer, and the up-regulation was
more common in lower-stage tumors. In addition,
increased ERRF expression was significantly associ-
ated with ER and/or progesterone receptor (PR) pos-
itivity, which was still valid in human epidermal
growth factor receptor 2 (HER2)–negative tumors. In
ER-positive tumors, ERRF expression was inversely
correlated with HER2 status. Furthermore, higher
ERRF protein expression was significantly associated
with better disease-free survival and overall survival,
particularly in ER- and/or PR-positive and HER2-nega-
tive tumors (luminal A subtype). Functionally, knock-
down of ERRF in two ER-positive breast cancer cell
lines, T-47D and MDA-MB-361, suppressed cell growthin vitro and tumorigenesis in xenograft models. These
results suggest that ERRF plays a role in estrogen-ER–
mediated growth of breast cancer cells and could, thus,
be a potential therapeutic target. (Am J Pathol 2012, 180:
1189–1201; DOI: 10.1016/j.ajpath.2011.11.025)
Breast cancer is a common malignancy that affects ap-
proximately one in eight women during their lifetime.1 In
the United States alone, an estimated 230,480 patients
will be diagnosed as having breast cancer in 2011, and
39,520 patients will die of the disease.1 At the time of
diagnosis, most breast cancers are positive for estrogen
receptor  (ER), and estrogen-ER signaling plays a nec-
essary role in the proliferation of cancer cells,2,3 which
has laid the foundation for antiestrogen therapy using
different approaches, including tamoxifen treatment. In
normal luminal breast epithelial cells, however, estro-
gen-ER signaling does not seem to be proproliferative; it
is, rather, necessary for the formation, maintenance, and
homeostasis of luminal epithelial cells.4 Normal ER-posi-
tive mammary epithelial cells are not proliferative, al-
though they are often adjacent to proliferative epithelial
cells in the breast.5–8 Consistently, in cultured nontumori-
genic yet ER-positive breast epithelial cells, estrogen in-
hibits cell proliferation.9–11 Therefore, estrogen-ER sig-
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normal and cancer breast epithelial cells, yet the molec-
ular basis for this difference is largely unknown. Further-
more, a substantial proportion of ER-positive breast can-
cers eventually fail to respond to antiestrogen therapies
and lead to patient death,12,13 and, thus, further under-
standing the conversion of ER function from prodifferen-
tiation in normal cells to proproliferation in cancer cells
should also help in improving antiestrogen therapy.
The putative uncharacterized C1orf64 gene (chromo-
some 1 open reading frame 64), also designated as
MGC24047 or RP11-5P18.4, was originally predicted
from DNA sequencing and biological annotation of hu-
man chromosome 1 and was validated by the detection
of a full-length cDNA sequence by the NIH Mammalian
Gene Collection Program.14,15 Based on the results de-
scribed in this study, we named the gene ERRF for ER-
related factor. The predicted ERRF/C1orf64 gene en-
codes a protein of 169 amino acid residues that does not
have known consensus domains. In a systematic analysis
of well-annotated human protein-coding genes for muta-
tions in 11 human breast cancers, Sjoblom et al16 iden-
tified two somatic mutations of this gene which led to
amino acid changes G52W and G100W, in a microdis-
sected primary tumor and the HCC1395 breast cancer
cell line. In addition, the chromosomal location of ERRF/
C1orf64, 1p36, is a target of genetic instability in human
breast cancer and melanoma.17,18 These findings sug-
gest that ERRF/C1orf64 may play a role in human breast
cancer.
To determine whether ERRF plays a role in breast
cancer development, we examined its mutation fre-
quency and expression at the RNA and protein levels in
a large number of breast cancers and correlated the
expression of ERRF with clinical and pathologic variables
of breast cancer. We also analyzed the functional effect
of ERRF on cell growth in vitro and on tumorigenesis in
xenograft models. Although the mutation of ERRF is in-
frequent in human breast cancer, its expression is signif-
icantly associated with ER and/or progesterone receptor
(PR) positivity and human epidermal growth factor recep-
tor 2 (HER2) negativity (luminal A subtype) in breast
cancer. In ER-positive breast cancer, higher expression
of ERRF protein was significantly associated with better
progression-free survival and overall survival (OS). Func-
tionally, knockdown of ERRF expression dramatically re-
tarded cell growth and tumorigenesis in the two ER-pos-
itive breast cancer cell lines tested.
Materials and Methods
Cell Lines, Primary Tumors, and Noncancerous
Breast Tissues
Thirty-five breast epithelial cell lines were used in this study,
including 31breast cancer cell lines (BRF-71T, BT-20, BT-474,
BT-549, BT-483, CAMA-1, DU4475, HCC1395, HCC1500,
HCC1599, HCC1806, HCC1937, HCC202, HCC2218,
HCC38, HCC70, Hs 578T, MCF7, MDA-MB-134, MDA-MB-
157, MDA-MB-175, MDA-MB-231, MDA-MB-361, MDA-MB-415, MDA-MB-453, MDA-MB-468, SW527, T-47D, UACC893,
ZR-75-1, ZR-75-30), 3 immortalized but nonneoplastic
breast epithelial cell lines (184A1, 184B5, and BRF-97T),
and 1 primary culture of human mammary epithelial cells
(Cambrex Corp., East Rutherford, NJ). Except for BRF-
97T and BRF-71T, which were from Biological Research
Faculty & Facility Inc. (Ijamsville, MD), all the cell lines
were purchased from American Type Culture Collection
(Manassas, VA) and were propagated as described pre-
viously.19 T-47D and MDA-MB-361, which were used in
functional experiments, were shown to be mycoplasma
free using the TaKaRa PCR mycoplasma detection kit
(TaKaRa Biotechnology Co. Ltd., Dalian, China). In addi-
tion, short tandem repeat profiling was conducted at the
Cancer Genomics Shared Resource of Emory Winship
Cancer Institute to verify the identity of seven cell lines,
including the two that were used for functional tests of
ERRF (T-47D, MDA-MB-361, 184A1, MCF-10A, Hs 578T,
MDA-MB-231, and ZR-75-1). Eight short tandem repeat
markers were profiled, including CSF1PO, D13S317,
D16S539, D5S818, D7S820, THO1, TPOX, and vWA. The
short tandem repeat profile for each cell line was com-
pared with its profile published by American Type Culture
Collection, and the authenticity of all seven cell lines was
confirmed.
A total of 367 breast cancer samples were used,
including 285 consecutive formalin-fixed, paraffin-em-
bedded primary tumor specimens used for protein ex-
pression analysis and 82 snap-frozen primary tumors
and their matched noncancerous breast tissues used
for RNA expression analysis (n  45) or gene mutation
analysis (n  48). Clinicopathologic variables, includ-
ing disease-free survival (DFS), were available for the
285 patients used for immunohistochemical (IHC)
study. In addition, 54 formalin-fixed, paraffin-embed-
ded noncancerous breast tissues, including 35 hyper-
plastic tissues from patients without breast cancer and
19 phenotypically normal tissues from patients with
breast cancer, were also used for ERRF protein ex-
pression study. An RNA sample from a pool of normal
breast tissues (Clontech, Mountain View, CA) was used
as a control. HER2 status was determined by IHC stain-
ing using the c-erbB2 Ab-17 monoclonal antibody
made by Neomarkers (clone designation: e2-4001 
3B5; Lab Vision, Fremont, CA). Based on IHC staining
signals, a scale of 0 to 3 was used to define HER2
protein expression: 0, no staining; 1, weak mem-
brane staining in 10% of cells; 2, moderate heter-
ogeneous complete membrane staining in 10% of
cells; and 3, uniform intense membrane staining in
30% of invasive tumor cells. Tumors with an IHC
score of 0 or 1 were considered HER2 negative, and
those with a score of 2 or 3 were considered HER2
positive.
All tissue specimens were obtained from the surgical
treatment of patients with breast cancer or breast hyper-
plasia at the Cancer Hospital of Tianjin Medical Univer-
sity. Use of the materials was approved by the hospital’s
ethics review committee. For the samples used for RNA
analysis, resected tissues were cut into small pieces and
then were snap frozen in liquid nitrogen immediately after
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were histologically confirmed.
Genomic DNA and total RNA were extracted by using
the DNeasy tissue kit (Qiagen, Shanghai, China) and the
TRIzol reagent (Invitrogen, Beijing, China), respectively,
according to the manufacturers’ manuals.
Mutation Analysis
Mutation analysis of the ERRF gene was performed as
described previously.16,20 Briefly, PCR primers flanking
the genomic DNA of each exon were synthesized based
on previously designed primer sequences.16,20 Forward
and reverse PCR primers are located 50 bp to the
exon-intron boundaries. A universal sequencing primer
(M13 forward, 5=-GTAAAACGACGGCCAGT-3=) was ap-
pended to the 5= end of one primer in a pair for sequenc-
ing. PCR products were purified and sequenced with the
M13 forward sequencing primer. Sequences were
aligned to the genomic reference sequences in the En-
trez gene database (Build 37.1). Any sequence changes
were considered as potential mutations, and the PCR
sequencing process was repeated for confirmation.
Semiquantitative RT-PCR and Quantitative
Real-Time PCR
Two micrograms of total RNA was reversely transcribed
into cDNA using the M-MLV reverse transcriptase (Pro-
mega, Beijing, China) following the manufacturer’s man-
ual. Primer sequences for semiquantitative RT-PCR were
5=-GCTGAAGTAGCCGCATGG-3= and 5=-CGGCCCTTC-
CAGCTAATC-3= for ERRF and 5=-ATCACTGCCACCCA-
GAAGAC-3= and 5=-ATGAGGTCCACCACCCTGTT-3= for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). PCR
amplification was performed in a volume of 20 L containing
2 L of cDNA, 0.25 mol/L of each primer, 0.25 mmol/L
of deoxyribonucleotide triphosphates, and 1 U of TaKaRa
TaqHS polymerase (TaKaRa Biotechnology Co. Ltd.) for
30 cycles. PCR products were electrophoresed in 1.5%
agarose gel containing ethidium bromide for visuali-
zation.
Quantitative real-time PCR was performed using the
SYBR Premix ExTaq reagent (TaKaRa Biotechnology Co.
Ltd.) in an iQ5 real-time PCR detection system (Bio-Rad
Laboratories, Beijing, China). Primer sequences for
real-time PCR were 5=-GAGCCAACCTCAAAGGC-3= and
5=-CCGTGGGTGCAGTCAATA-3= for ERRF and 5=-
GGTGGTCTCCTCTGACTTCAACA-3= and 5=-GTTGCTG-
TAGCCAAATTCGTTGT-3= for GAPDH. Expression of the
ERRF gene in each sample was defined by normalizing
the CT (CT
ERRF – CT
GAPDH) for the sample against the
CT for the pool of normal breast tissues from Clontech,
assuming that the ERRF expression level in this pool of
normal tissues presents its average expression level in
normal breast.IHC Staining
Tissue microarray slides containing 285 formalin-fixed,
paraffin-embedded breast cancer tissues were used to
detect ERRF protein expression by IHC staining. In ad-
dition, 54 formalin-fixed, paraffin-embedded noncancer-
ous breast tissues were used to monitor ERRF expression
in noncancerous breast cancer tissues. Briefly, after
deparaffinization in xylene and rehydration in a series of
alcohols (100  75%), slides were incubated in the dual
endogenous enzyme block (Dako, Carpinteria, CA) for 15
minutes to inactivate endogenous peroxide activity and
were treated in citrate buffer (pH 6.0) for 3 minutes in a
pressure cooker for antigen retrieval. After cooling for 45
minutes at room temperature, slides were incubated with
rabbit anti-ERRF antibody (HPA026676; Sigma-Aldrich,
St. Louis, MO) at 1:600 dilution at 4°C overnight and with
the secondary horseradish peroxidase–labeled polymer
anti-rabbit Igs (Dako) for 30 minutes at room temperature.
With diaminobenzidine tetrahydrochloride (Dako) as a
chromogen, slides were counterstained with hematoxylin.
Preimmune serum was used as the negative control for
ERRF antibody. The specificity of ERRF antibody was
evaluated by IHC staining of T-47D (ERRF-positive) and
MCF-7 (ERRF-negative) breast cancer cell lines pre-
pared in paraffin blocks (see Supplemental Figure S1 at
http://ajp.amjpathol.org).
Slides with IHC staining were examined independently
by two investigators (X.F. and S.F.), and any discrepancy
in the reading for a case was discussed and resolved.
The intensity of nuclear staining (0  negative, 1  low,
2  medium, and 3  high) and the percentage of pos-
itively stained cells (0  100%) were recorded for each
specimen, and ERRF expression was expressed as the
multiplied score, which was calculated as intensity
score percentage for positive cells 100. The average
multiplied score for the 54 noncancerous breast tissues
was 15. In addition, the median of ERRF expression
levels in primary tumors was 15. Therefore, the cutoff
point of 15 was used to classify primary tumors into two
groups. Those with a multiplied score 15 were defined
as lower ERRF expression, and those with a multiplied
score 15 were defined as higher ERRF expression. We
also used the receiver operating characteristic curve to
determine the optimal cutoff points for ERRF expression.
In this analysis, the optimal cutoff point is defined when
the Youden Index, the potential effectiveness of a bio-
marker, achieved the maximum.21 With the Youden cutoff
point, which varied among different variables, tumors
were regrouped as ERRF higher or ERRF lower, and
statistical analysis was performed again for each vari-
able.
Cell Proliferation and Survival Assay in Vitro
Two different Stealth RNA interference (RNAi) small-inter-
fering RNAs (siRNAs) for the ERRF gene were purchased
from Invitrogen, and a nontarget control siRNA was pur-
chased from Rui Bo (Guangzhou, China). Compared with
traditional siRNA duplexes, Stealth RNAi siRNA has pro-
prietary chemical modifications that make such siRNA
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gene knockdown, and less stressful to cells. The target
sequence of siM1 siRNA was 5=-GGCTGCGCCTGTGAG-
GTCTTCAACT-3= and that of siM2 siRNA was 5=-
GGGAACAGTCAAGGACTCACTGAAA-3=. T-47D and
MDA-MB-361 cells were seeded into 24-well plates at a
density of 5  104 per well. On the following day, siRNA
transfection was conducted using the Lipofectamine
RNAiMAX transfection reagent (Invitrogen). At set times
after transfection, cells were fixed with 10% trichloro-
acetic acid, stained with 0.4% sulforhodamine-B, and
washed by 1% acetic acid. The optical densities, which
indicate cell numbers, were measured using an EMax
Precision microplate reader (Molecular Devices, Shang-
hai, China) at a 490-nm wavelength. Each treatment was
in triplicate.
In Vivo Tumorigenesis Assay
T-47D and MDA-MB-361 cells were transiently transfected
with the same siRNAs against ERRF or control as described
previously herein. Use of the Stealth RNAi siRNA could
maintain the knockdown of ERRF for at least 7 days in vitro,
so transiently transfected cells were used in the tumorigen-
esis assay. Forty-eight hours later, cells were injected sub-
cutaneously into the right flank of 6-week-old female BALB/c
nude mice at 5  106 cells per site. Some cells were used
in real-time PCR assay to confirm the knockdown of ERRF in
both cell lines. Three days before the injection, 17-estra-
diol pellets (0.72 mg per pellet, 60-day release; Innovative
Research of America, Sarasota, FL) were implanted into the
left flanks of mice. Eight mice were used for each treatment
in each group. Tumor volumes were measured weekly us-
ing a vernier caliper. Four or five weeks after injection,
tumors were removed and tumor weights were measured.
Test of ERRF Antibody in Cells with Known
ERRF Expression Status
T-47D (ER positive and ERRF positive) and MCF-7 (ER
positive but ERRF negative) cells were collected in PBS,
fixed in 10% buffered formalin for 2 hours at room tem-
perature, and centrifuged and resuspended in 300 L of
PBS. After adding 600 L of 3% low–melting point aga-
rose in PBS, cell solution was chilled on ice, gelled pellet
was removed and trimmed, and paraffin block was pre-
pared. Sections were made and were subjected to IHC
staining as with tissue sections.
Apoptosis Analysis
T-47D cells transfected with the siM1 siRNA against
ERRF or the control siRNA for 2 days were subjected to
apoptotic assay. Using the fluorescein isothiocyanate an-
nexin V apoptosis detection kit from BD Pharmingen
(Shanghai, China), cells were stained with annexin V–flu-
orescein isothiocyanate and then were flow sorted follow-
ing a standard protocol. Briefly, cells floating in the me-
dium and attached to the plate were collected, washed
with cold PBS, and resuspended in 1 binding buffer[0.01 mmol/L HEPES (pH 7.4), 0.14 mol/L NaCl, and 2.5
mmol/L CaCl2] at a concentration of 2  10
6 cells/mL.
One hundred microliters of cell solution was transferred
into a 5-mL culture tube, and 5 L of annexin V and
propidium iodide were added. After gentle mixing and
incubation for 15 minutes at room temperature in the
dark, 400 L of the 1 binding buffer was added, and
cells were analyzed by flow cytometry within 1 hour.
Cell-Cycle Analysis
T-47D cells transfected with the siM1 siRNA against ERRF
or the control siRNA for 2 days were stained with propidium
iodide and subjected to flow cytometry following a stan-
dard. Briefly, cells were collected and washed twice with
cold PBS, fixed in 10 mL of 70% ethanol at 20°C over-
night, washed again with PBS, stained with 0.5 mL of pro-
pidium iodide/RNase staining buffer for 15 minutes at room
temperature, and analyzed by flow cytometry.
Statistical and Survival Analyses
The association between ERRF expression and clinicopath-
ologic variables was examined using the 2 test or the
Fisher exact test. Kaplan-Meier survival analysis was used
to calculate DFS or OS rates in different groups of patients.
Multivariate Cox regression analysis was used to determine
whether ERRF expression was independent of other prog-
nostic factors. Data from cell proliferation in vitro and tumor-
igenesis in vivo were analyzed by Student’s t-test. All re-
ported P values were 2-tailed. SPSS, version 15.0 (SPSS
Inc, Chicago, IL) was used for statistical analysis.
Results
Infrequent Mutation of ERRF in Breast Cancer
In the 31 breast cancer cell lines and 48 primary breast
tumors analyzed, only one mutation (G366T/G100W,
homozygous) was detected in one sample (the
HCC1395 breast cancer cell line). The same mutation
in the same cell line was reported in a previous study.16
Four single nucleotide polymorphisms (SNPs) were
identified, each with different frequencies. SNP rs1763617
(C86T) showed a C/T heterozygosity in 4 breast cancer
cell lines (BRF-71T, BT-20, HCC1806, and ZR-75-1) and
in 15 primary tumors and a T/T homozygosity in five
primary tumors but in no cell lines. SNP rs1763612
(C308T) was heterozygous in one cell line (HCC1806)
and in two primary tumors; SNP rs34950166 (C402T)
showed T/T in two cell lines (BT-483 and HCC202) but in
no primary tumors; and SNP rs3738646 (T416C) was
heterozygous in three cell lines (BRF-71T, BT-20, and
ZR-75-1) and in 15 primary tumors and was homozygous
C/C in five primary tumors but in no cell lines. No other
cancer-specific sequence alterations were found in 79
breast cancers, suggesting that the ERRF mutation is
relatively infrequent in breast cancer.
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Associated with ER Positivity in Cell Lines and
Primary Tumors from Breast Cancer
We evaluated the expression of ERRF in normal and
cancer cells of the breast. According to SAGEmap, a
public gene expression resource based on the serial
analysis of gene expression (SAGE) approach,22 the ex-
pression of ERRF is restricted to a few normal tissues,
including the brain, cortex, retina, and thyroid. It was not
detected in the bladder, bone marrow, breast, cervix,
colon, heart, kidney, liver, lung, lymph node, muscle,
Table 1. Association of ERRF mRNA Expression with Clinicopath
Cancer
Variable Total cases
Normal
ERRF lower ERRF hig
Age (years)
50 14 11 3
50 31 11 20
Stage
I/II 23 11 12
III/IV 7 3 4
Grade
I 3 3 0
II 23 10 13
III 10 4 6
Lymph
node
 17 8 9
 26 13 13
ER
 23 12 11
 22 10 12
PR
 28 14 14
 17 8 9
HER2
 20 12 8
 25 10 15
Data are given as number of patients. Higher or lower ERRF RNA expre
tissues purchased from Clontech.
*P values were determined using the 2 test.ovary, pancreas, placenta, prostate, salivary gland, skin,
spinal cord, spleen, testis, or thymus. Breast and prostate
cancers are the only two other tissues that showed de-
tectable expression of ERRF in the SAGE database. We,
therefore, examined the expression of ERRF mRNA by
using PCR-based approaches in malignant and nonma-
lignant tissues and cell lines from the breast (Figure 1 and
Table 1). Whereas ERRF mRNA was not detectable in
cultured nonmalignant breast epithelial cells, including
primary culture of human mammary epithelial cells and
the immortalized breast epithelial cell lines 184A1,
184B5, and BRF-97T, it was clearly detected in a pool of
Figure 1. Expression of ERRF mRNA is associ-
ated with ER positivity in cell lines and primary
tumors of breast cancer. A: Detection of ERRF
mRNA in breast epithelial cell lines by regular
and real-time RT-PCR. GAPDH was used as an
internal control. The numbers in parentheses
after each cell line are CT values detected by
real-time PCR. Asterisks indicate normal breast
tissues or immortalized non-tumorigenic epithe-
lial cell lines. B: Representative results of ERRF
mRNA expression in primary breast cancer sam-
ples (C) and adjacent noncancerous tissues (N).
Samples 1, 2, and 3 are ER positive, whereas
samples 4 and 5 are ER negative. C: Expression
of ERRF mRNA, detected by real-time PCR, in the
same samples as in B. Error bars represent SD.
Variables in Normal and Tumor Cells of 45 Patients with Breast
P value*
Tumor
P value*ERRF lower ERRF higher
0.006 6 8 0.344
18 13
0.817 10 13 0.526
4 3
0.089 1 2 0.305
10 13
7 3
0.850 8 9 0.663
14 12
0.652 7 16 0.002
17 5
0.848 12 16 0.071
12 5
0.182 10 10 0.688
14 11
as relative to the ERRF expression level in a pool of human normal breastologic
her
ssion w
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cerous tissues from 45 breast cancers, ERRF mRNA ex-
pression showed a diverse range, with an average CT,
which indicates expression levels in real-time PCR of
7.4. The CT for the pool of normal breast tissues from
Clontech was 7.42, which was almost identical to that for
the 45 noncancerous samples, suggesting that ERRF
expression in normal and noncancerous breast tissues is
consistent among different samples. Therefore, the aver-
age ERRF expression level from the pool of normal breast
tissues could serve as the cutoff point for the correlation
analysis, and we defined the samples with a CT value
7.4 as ERRF higher and those with a CT value7.4 as
ERRF lower. ERRF RNA expression was positive in 23 of
the 45 samples (51%) (Table 1). These results suggest
that ERRF is transcribed in nonmalignant breast tissues
but not in cultured breast epithelial cells.
In the 31 breast cancer cell lines examined, ERRF
mRNA was detected in 17 (55%), including BT-474, BT-
483, CAMA-1, DU4475, HCC1500, HCC202, HCC2218,
MDA-MB-134, MDA-MB-175, MDA-MB-361, MDA-MB-
415, MDA-MB-453, SW527, T-47D, UACC893, ZR-75-1,
and ZR-75-30, although the expression in MDA-MB-134
and MDA-MB-175 was rather weak (Figure 1A). ERRF
was not detectable in the remaining 14 cell lines (45%),
including BRF-71T, BT-20, BT-549, HCC1395, HCC1599,
HCC1806, HCC1937, HCC38, HCC70, Hs 578T, MCF7,
MDA-MB-157, MDA-MB-231, and MDA-MB-468 (Figure
1A and data not shown). ERRF was highly expressed in
11 of the 12 ER-positive cell lines (92%)23,24 but was
undetectable in 13 of the 19 ER-negative lines (68%)
(Figure 1A and data not shown). The Fisher exact test on
ERRF expression and ER positivity in these cell lines
indicated that ERRF mRNA expression is significantly
associated with ER positivity (P  0.002).
When the 31 cell lines were stratified by HER2 status,
the association between ERRF expression and ER posi-
tivity became more obvious in HER2-negative breast can-
cers, as 8 of 9 ER-positive and HER2-negative cell lines
(89%) but only 2 of 15 ER- and HER2-negative lines
(13%) expressed ERRF (P  4.9  10-4, Fisher exact
test). In the HER2-positive group, three cell lines (BT474,
MDA-MB-361, and ZR-75-30) were ER positive and four
cell lines (HCC2218, HCC202, MDA-MB-453, and
UACC893) were ER negative. ERRF expression was not
significantly associated with ER expression in these
HER2-positive breast cancer cell lines.
Of the 45 primary breast tumors, 21 (47%) showed
higher ERRF RNA expression, and the remaining 24 were
lower (Figure 1, B and C, and Table 1). Compared with
matching noncancerous tissues, 17 of the 45 tumors
showed down-regulation of ERRF, 14 showed no change,
and 14 showed up-regulation. We then correlated ERRF
mRNA expression with various characteristics of breast
cancer, including age at diagnosis, tumor stage, tumor
grade, lymph node status, and the status of ER, PR, or
HER2 (Table 1). Only ER showed a significant correlation
with ERRF expression, as 16 of 23 ER-positive tumors
(70%) but only 5 of 22 ER-negative tumors (23%) were
ERRF higher (P  0.002). There also seemed to be anassociation between ERRF expression and PR positivity,
but it did not reach a significant level (P  0.071).
We also retrieved microarray-based expression data
for breast cancer from the Oncomine database to further
evaluate the association between ERRF mRNA expres-
sion and ER status. Oncomine is a cancer microarray
database integrated with a data-mining platform.25 There
were eight independent data sets in which ER expression
was either positive or negative in at least 10 cases. The
expression of ERRF mRNA was significantly higher in ER-
positive tumors than in ER-negative tumors in each of the
eight data sets, further supporting an association between
ERRF expression and ER positivity in breast cancer.
ERRF Protein Expression Significantly Correlates
with ER or PR Positivity, Which Was also True in
HER2-Negative Breast Cancers when Stratified
with HER2 Status
To further evaluate the association of ERRF expression
with ER status, we performed IHC staining with tissue
microarray slides of 285 breast cancers and 54 noncan-
cerous tissues. In phenotypically normal breast luminal
cells, ERRF protein was clearly detected, and the staining
was primarily located in the nucleus although also visible
in the cytoplasm of some cells (Figure 2). In some non-
cancerous tissues, ERRF staining was stronger, but, in
general, it was still weaker compared with tumors that
stained high for ERRF. In breast cancer samples, ERRF
protein was expressed at varying levels, with strong
staining in some tumors but lower or even absent staining
in other tumors (Figure 2 and Table 2). Compared with
ER-negative tumors, ERRF expression was significantly
Figure 2. Detection of ERRF protein expression in breast tissues by IHC
staining. N1 and N2, two representative noncancerous breast tissues; T1, T2,
and T3, three representative breast cancer tissues showing different decreas-
ing levels of ERRF expression; IgG, breast cancer tissue T2 stained with
preimmune rabbit IgG (negative control).
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RNA expression results.
When the tumors were stratified by HER2 status, the
association between ERRF expression and ER positivity
was detectable in HER2-negative tumors only, as 74 of
103 ER-positive tumors (72%) versus 22 of 42 ER-nega-
tive tumors (52%) express ERRF (P  0.025; Table 3),
which is consistent with the results from the 31 breast
cancer cell lines. Also consistent with cell line results,
ERRF expression showed a strong association with PR
positivity in the HER2-negative tumors, as 68 of 90 PR-
positive tumors (76%) versus 28 of 55 PR-negative tu-
mors (51%) express ERRF (P 0.002; Table 3). In HER2-
positive tumors (n  140), ERRF expression did not show
an association with either ER or PR (Table 3).
Because the cross-talk between ER, PR, and HER2
signaling plays an important role in the development and
progression of breast cancer,26,27 breast cancers are
categorized into four groups based on the expression
status of ER, PR, and HER2: luminal A (ER positive and/or
PR positive, HER2 negative), luminal B (ER positive
and/or PR positive, HER2 positive), basal-like triple neg-
ative (ER negative, PR negative, and HER2 negative),
and HER2 positive (ER negative, PR negative, and HER2
positive).28,29 Consistent with a positive correlation be-
tween ERRF and ER or PR in HER2-negative tumors, we
found that ERRF expression was significantly higher in
luminal A tumors than in luminal B, triple-negative, or
Table 2. Association of ERRF Protein Expression with Clinical an
Variable Total cases
E
Low
Age (years)
50 108 59/5
50 173 80/6
Tumor size
(cm)
2 64 30/3
2 217 110/1
Stage
I/II 209 96/9
III/IV 69 42/4
Grade
I/II 222 127/1
III 49 28/3
Lymph node
 153 76/1
 132 67/1
ER
 170 70/6
 115 73/7
PR
 166 74/9
 119 69/8
HER2
 140 94/1
 145 49/7
Data are given as number of tumors. Higher or lower ERRF expression wa
or the optimal cutoff point determined by the Youden Index (Y) in tumors, whi
for lymph node status, 11.5 for ER status, 38 for PR status, and 41.5 for HE
*P values were determined by using the Pearson 2 test, and HER2 s
†The P value became smaller than 0.05 after the optimal cutoff pointHER2-positive tumors (Table 4).ERRF Expression Inversely Correlates with
HER2 Positivity in ER-Positive Breast Cancer
In the 31 breast cancer cell lines, ERRF expression was
detectable in 7 of the 7 HER2-positive lines but in only 10 of
the 24 HER2-negative lines (42%) (P  0.009, Fisher exact
test; Table 3), suggesting a correlation between ERRF ex-
pression and HER2 positivity in breast cancer cell lines.
In primary tumors, however, ERRF expression showed an
inverse correlation with HER2 positivity, as 96 of 145 HER2-
negative tumors (66%) but only 46 of 140 HER2-positive
tumors (33%) had ERRF expression (P  0.001; Table 3).
When we stratified tumors by ER status, the inverse corre-
lation between ERRF and HER2 expression was still signif-
icant. In the ER-positive group, 74 of 103 HER2-negative
tumors (72%) and 26 of 67 HER2-positive tumors (39%) had
ERRF expression; in the ER-negative group, 22 of 42 HER2-
negative tumors (52%) and 20 of 73 HER2-positive tumors
(27%) had ERRF expression (Table 5).
Higher ERRF Expression Correlates with Older
Age at Diagnosis, Lower Tumor Stage, Lower
Tumor Grade, and Less Lymph Node
Metastasis in Breast Cancer
When the median level of ERRF expression was used to
group tumors into ERRF higher and ERRF lower, ERRF
ologic Variables in 285 Primary Tumors from Breast Cancer
xpression (M/Y)
P value (M/Y)*Higher
49/57 0.171/0.046†
93/112
34/30 0.592/0.170
107/81
113/113 0.031/0.031
27/27
95/118 0.192/0.035†
21/13
77/11 0.855/0.048†
65/19
100/105 0.0002/5.34  105
42/43
92/73 0.026/0.002
50/31
46/23 1.81  108/1.39  109
96/73
e to the median (M) IHC staining score of 15 for noncancerous breast tissues
7.5 for age, 31.5 for tumor size, 14 for tumor stage, 34 for tumor grade, 132.5
s.
as defined by IHC staining.
ned by the Youden Index was applied.d Path
RRF e
er
1
1
4
36
6
2
04
6
42
13
5
2
3
8
17
2
s relativ
ch was
R2 statuexpression seemed to correlate with lower tumor stage,
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AJP March 2012, Vol. 180, No. 3as 113 of 209 stage I or II tumors (54%) were higher for
ERRF expression but only 27 of 69 stage III or IV tumors
(39%) were lower (Table 2; P  0.031). There was no
significant association between ERRF expression and
age at diagnosis, tumor size, tumor grade, or lymph node
status when the median ERRF expression level was used
as the cutoff point (Tables 1 and 2). When the cutoff point
of ERRF expression was defined by the Youden Index for
each variable, however, higher ERRF expression showed
a significant association with older age at diagnosis,
lower tumor grade, and less lymph node metastasis (Ta-
ble 2). Of the tumors that had higher levels of ERRF
expression, 112 of 169 (66%) occurred in women 50
Table 3. Positive Association of ERRF Expression with ER and PR
Status Is Statistically Significant in Only HER2-Negative
Primary Tumors (n  145) and Cell Lines (n  24)
Group ER/PR Cases
ERRF
expression
P value*Lower Higher
Primary
tumors
HER2 145 49 96 0.038†
ER 103 29 74 0.025
ER 42 20 22
PR 90 22 68 0.002
PR 55 27 28
HER2 140 94 46 0.001†
ER 67 41 26 0.151
ER 73 53 20
PR 76 52 24 0.726
PR 64 42 22
Cell lines
HER2 24 14 10
ER 9 1 8 4.90  104
ER 15 13 2
PR 5 1 5 0.015
PR 19 13 5
HER2 7 0 7
ER 3 0 3
ER 4 0 4
PR 2 0 2
PR 5 0 5
Data are given as number of tumors. ERRF expression in primary
tumors was based on IHC staining, and that in cell lines was based on
real-time PCR. The median of IHC staining scores from tumors was used
as the cutoff point for protein expression, whereas the reading of real-time
PCR from a pool of normal breast tissues was used as the cutoff point for
cell lines.
*P values were determined using the 2 test.
†P values are for the comparison between primary breast cancer
tumors and breast cancer cell lines.
Table 4. Differential Expression of ERRF Protein in Luminal A (L
(HER2) Subtypes of Breast Cancer
Type Cases (no.)
ERRF expression
(mean 	 SD)
LuA 113 73.76 	 7.16
LuB 91 23.68 	 3.93
TN 33 44.36 	 10.57
HER2 48 18.71 	 4.96*P values were determined using the Tukey test.
†P value was determined using the F test with the general linear model.years or older and 57 of 169 (34%) occurred in women
younger than 50 years (P 0.046); 118 of 131 (90%) had
a lower tumor grade, but only 13 of 131 (10%) had a
higher tumor grade (P  0.035); and 19 of 30 (63%) were
negative for lymph node metastasis, whereas 11 of 30
(37%) were positive (P  0.048) (Table 2).
Higher ERRF Expression Correlates with Better
Prognosis in Breast Cancer
We then determined whether ERRF protein expression is
associated with DFS or OS in the 285 patients with breast
cancer stratified according to the expression status of
ER, PR, or HER2 (data not shown). In univariate analysis,
ERRF up-regulation showed an association with DFS and
OS, along with tumor stage, tumor grade, and lymph
node metastasis (Table 6). Patient age at diagnosis, tu-
mor size, ER positivity, PR positivity, and HER2 positivity
did not show a significant association with survival. Pa-
tients with higher ERRF expression (n  142) had signif-
icantly better DFS than did those with lower ERRF expres-
sion (n  143; P  0.029; Figure 3A). Kaplan-Meier
minal B (LuB), Triple-Negative (TN), and HER2-Positive
P value*
Overall
P value†LuA LuB TN
5.8  10-10
8  10-8
0.053 0.299
4  10-7 0.964 0.208
Table 5. Inverse Correlation between ERRF Expression and
HER2 Status Is Statistically Significant in Primary
Tumors Regardless of ER Status, Although the
Association Was Not Significant in Cell Lines
Group HER2 Cases
ERRF
expression
P value*Lower Higher
Primary tumors
ER 170 70 100 0.051†
 67 41 26 1.9  10-5
 103 29 74
ER 115 73 42 0.874†
 73 53 20 0.007
 42 20 22
Cell Lines
ER 12 1 11
 3 0 3 0.546
 9 1 8
ER 19 13 6
 4 0 3 
 15 13 2
Data are given as number of tumors. ERRF expression in primary
tumors was based on IHC staining of ERRF protein, and that in cell lines
was based on real-time PCR of ERRF RNA.
*P values were determined using the 2 test.
†P values are for the comparison between primary breast cancer
tumors and breast cancer cell lines.uA), Lu
1.
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AJP March 2012, Vol. 180, No. 3survival analysis showed that patients with higher ERRF
expression had significantly less chance of recurrence
than did those with lower ERRF expression (P  0.009;
Figure 3B). Then we analyzed ERRF and DFS in ER-
positive and ER-negative patients. Kaplan-Meier survival
analysis further demonstrated that patients with higher
Table 6. Identification of Survival Factors Using Cox Proportiona
Backward Stepwise Logistic Regression
Variable
DFS
Hazard ratio 95% CI
Univariate Analysis
ERRF (n  283) 0.382 0.182 to 0.80
Age (n  279) 1.235 0.596 to 2.56
Tumor size (n  279) 1.115 0.484 to 2.56
Stage (n  276) 2.230 1.109 to 4.48
Grade (n  269) 2.186 1.034 to 4.61
Lymph node (n  283) 2.103 1.001 to 4.41
ER (n  283) 1.461 0.694 to 3.07
PR (n  283) 1.088 0.541 to 2.18
HER2 (n  283) 1.346 0.676 to 2.67
Multivariate Analysis*
ERRF 0.361 0.167 to 0.77
Grade 1.993 0.912 to 4.35
Lymph node 1.976 0.897 to 4.35
ER 1.896 0.867 to 4.14
*Based on backward stepwise logistic regression (n  260).
CI, confidence interval.
Figure 3. Association between ERRF expression and DFS or OS in patients
with breast cancer. A: Number of patients with higher or lower ERRF ex-
pression, recurrence, and death. B–E: Kaplan-Meier analysis of ERRF expres-
sion and DFS (B and C) and OS (D and E) in all 285 patients (B and D) and
in patients who had the luminal A subtype of breast cancer (C and E). P
values were from the log-rank univariate test and are, thus, different from
those derived from Cox regression tests.ERRF expression had significantly less chance of recur-
rence in ER-positive patients (P 0.002, data not shown)
but not in ER-negative patients (data not shown), in PR-
positive patients (P  0.002, data not shown) but not in
PR-negative patients (data not shown), and in HER2-
negative patients (P  0.008, data not shown) but not in
HER2-positive patients (data not shown). As expected,
patients with higher ERRF expression had less chance of
recurrence in the luminal A subtype of breast cancer,
which is defined as ER and/or PR positive and HER2
negative (P  0.005; Figure 3C).28,29
Patients with higher ERRF expression (n  142; Figure
3A) also showed better OS (P  0.017; Figure 3D), and a
significant association was detected in patients whose
tumors were ER positive (P  0.019), PR positive (P 
0.004), or luminal A subtype (P  0.041; Figure 3E) but
not in patients with ER- or PR-negative tumors (data not
shown). There was also a trend toward association be-
tween OS and HER2 negativity, but it did not reach a
significant level (P  0.055).
Multivariate analysis of all patients based on backward
stepwise logistic regression showed that the association of
higher ERRF expression with better DFS was independent
of known survival factors, such as lymph node metastasis
and tumor grade (P  0.009; Table 6). For OS, ERRF ex-
pression showed a trend toward association, but it did not
reach a significant level (P  0.057; Table 6), whereas
lymph node metastasis showed a significant association.
Knockdown of ERRF by RNAi Inhibits the
Growth of ER-Positive Breast Cancer Cells
in Vitro
ER is required for the growth of most ER-positive breast
cancers, and targeting ER by tamoxifen is an effective
therapy for breast cancer.13 Based on the significant
association between ERRF expression and ER positivity
rd Ratio Univariate and Multivariate Analyses Based on
OS
P value Hazard ratio 95% CI P value
0.011 0.302 0.108 to 0.844 0.022
0.570 1.612 0.575 to 4.522 0.364
0.798 1.171 0.388 to 3.532 0.780
0.024 2.561 1.022 to 6.413 0.045
0.040 3.136 1.210 to 8.128 0.019
0.050 3.410 1.131 to 10.283 0.029
0.318 0.765 0.302 to 1.936 0.571
0.813 0.925 0.370 to 2.311 0.867
0.398 1.698 0.669 to 4.313 0.265
0.009 0.358 0.124 to 1.029 0.057
0.084 2.397 0.898 to 6.402 0.081
0.091 3.835 1.092 to 13.472 0.036
0.109l Haza
5
2
9
5
9
8
4
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8
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8described previously herein (Figures 1 and 2 and Tables
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AJP March 2012, Vol. 180, No. 31 and 2), we tested whether ERRF plays a role in estro-
gen-mediated cell growth in ER-positive breast cancer
cells. We chose the T-47D and MDA-MB-361 breast can-
cer cell lines for these experiments because they are ER
positive and express higher levels of ERRF (Figure 1).
When the expression of ERRF was knocked down by
transfecting siRNAs into cells, as confirmed by RT-PCR
for two different siRNAs, cell growth was significantly
inhibited in the T-47D and MDA-MB-361 cell lines by both
siRNAs, although the two siRNAs could have different
potency (Figure 4). This experiment was repeated four
times for the T-47D cell line and three times for the MDA-
MB-361 cell line, and similar results were obtained. These
results suggest that ERRF plays a role in the growth of
ER-positive breast cancer cells.
To evaluate whether cell-cycle arrest or apoptosis is
responsible for the decrease in cell numbers on the
knockdown of ERRF, we conducted flow cytometry anal-
ysis of T-47D cells stained with annexin V–fluorescein
isothiocyanate and propidium iodide. Whereas stauro-
sporine, a potent apoptosis inducer, caused a significant
level of cell death (9.7%) compared with the dimethyl
sulfoxide solvent control (1%), neither the control siRNA
nor the ERRF siRNA (siM1) had an obvious effect on cell
death (see Supplemental Figure S2, A–D, at http://ajp.
amjpathol.org). On the other hand, knockdown of ERRF
significantly increased the number of cells in the G0/G1
phase and decreased the number of cells in the S and
G2/M phases (see Supplemental Figure S2E at http://
ajp.amjpathol.org). Therefore, siM1-mediated knockdown
of ERRF causes cell-cycle arrest rather than cell death at
least in T-47D cells.
Knockdown of ERRF Inhibits Tumor Growth in
Xenograft Models
To further determine the effect of ERRF on the growth of
ER-positive breast cancer cells, we also injected T-47D
and MDA-MB-361 cells transfected with siRNAs against
ERRF into female BALB/c nude mice and measured tu-
mor volume and weight. Higher levels of estrogen were
achieved by subcutaneously transplanting hormone pel-
lets. Consistent with the in vitro results, knockdown of
ERRF significantly suppressed tumor growth in both cell
lines (Figure 5). These results further indicate that ERRF
is involved in the growth of ER-positive breast cancer
cells.
Discussion
In this study, we examined a predicted gene that had two
mutations in 11 breast cancers,16 C1orf64, for its poten-
tial role in breast cancer. We examined its mutation, ex-
pression, and functional effect on cell and tumor growth
in breast cancer cells. Except for a previously reported
mutation in the HCC1395 breast cancer cell line,16 no
other mutations were detected in 78 breast cancers, al-
though several SNPs were detected in these samples.
ERRF expression significantly correlates with ER and
PR status in HER2-negative breast cancer. This conclu-sion is based on the analysis of ERRF RNA and protein in
cell lines and primary tumors from breast cancer (Figures
1 and 2 and Tables 1–3). The association with ER status
was significant in cell lines and primary tumors and at
RNA and protein levels in primary tumors (Tables 1 and
Figure 4. Knockdown of ERRF suppresses cell proliferation in T-47D and
MDA-MB-361 breast cancer cell lines. A and B: Confirmation of ERRF knock-
down in both cell lines by RT-PCR (A) and real-time PCR (B) in cells
transfected with siRNA for 2 days. Control, control siRNA; siM1 and siM2, two
different ERRF siRNAs from Invitrogen. Error bars represent SD. C and D:
Growth curves of T-47D (C) and MDA-MB-361 (D) cells with ERRF knock-
down for 1 to 10 days. OD, optical density of lysed cells.2), which suggests that ERRF is transcriptionally up-reg-
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PR status became more significant after the tumors were
stratified by HER2 status (P value changed from 0.027 in
all tumors to 0.002 in HER2-negative tumors; Table 3).
Note that the association between ERRF and ER or PR
did not exist in HER2-positive tumors (Table 3).
ERRF expression inversely correlated with HER2 status
regardless of ER status in primary tumors (Tables 2 and
Figure 5. Knockdown of ERRF suppresses the tumorigenesis of T-47D and
MDA-MB-361 breast cancer cell lines in nude mice. A: Confirmation of ERRF
knockdown by RT-PCR in the two cell lines (T-47D and MDA-MB-361)
transfected for 2 days (left panel) or in T-47D cells transfected for 7 days
(right panel). Ctrl, control. B and C: Plot of tumor volume against time after
tumor cells were injected into nude mice for T-47D (B) and MDA-MB-361 (C)
cells.D: Tumor weight at the end of the xenograft experiments for T-47D and
MDA-MB-361 cell lines with ERRF knockdown. Error bars represent SD.3). It has been demonstrated previously that ER expres-sion also inversely correlates with HER2 in breast can-
cer,30–32 which further suggests a functional interaction
between ER and ERRF in breast epithelial cells. Opposite
to this inverse correlation in primary tumors, all seven
HER2-positive cell lines and only 10 of the 24 HER2-
negative cell lines (42%) express ERRF compared with a
frequency of 96 of 145 in HER2-negative primary tumors
(66%) (Table 3). It is unknown whether this discrepancy
between cell lines and primary tumors has biological
significance as the number of cell lines available for anal-
ysis was rather small. In addition, it is well-known that cell
lines are different from primary tumors in many aspects,
and they can acquire or present additional or different
features due to in vitro culture, homogeneity, selection for
proproliferative cells, etc. One speculation is that ERRF is
involved in the establishment and growth of HER2-posi-
tive breast cancer cell lines in vitro.
A positive correlation of ERRF with ER and PR and a
negative correlation with HER2 suggest that ERRF is
highly expressed in the luminal A subtype of breast can-
cer (ER and/or PR positive, HER2 negative). This is,
indeed, the case, as luminal A tumors expressed signif-
icantly higher levels of ERRF than did luminal B or triple-
negative tumors (Table 4). Patients with the luminal A
subtype of breast cancer survive better than do those
with luminal B or triple negative,33,34 and as discussed
later herein, ERRF expression is, indeed, associated with
better patient survival.
Although ERRF expression is significantly increased in
breast cancers, higher ERRF expression predicts better
patient survival. For example, higher ERRF expression
was associated with older age at diagnosis, lower tumor
stage, lower tumor grade, and less lymph node metasta-
sis (Table 2), which are established prognostic factors in
breast cancer. Indeed, higher ERRF expression was sig-
nificantly associated with better DFS and OS in the pa-
tients examined, along with lower tumor grade, lower
tumor stage, and less lymph node metastasis (Table 6).
The prognostic function of ERRF expression seems to be
independent of the other three prognostic factors at least
for DFS, as determined by the multivariate analysis (Table
6). The association of ERRF expression with patient sur-
vival became more significant in ER-positive tumors but
disappeared in ER-negative patients, suggesting that ER
positivity could drive the association between higher
ERRF expression and better prognosis. It is possible that
in ER-positive breast cancer, lower ERRF expression
could promote tumor recurrence and metastasis.
ERRF is necessary for ER-positive breast cancer cells
to proliferate. Estrogen-ER signaling regulates many
genes in the mammary gland and breast cancer, and
most of them are not directly involved in estrogen-mod-
ulated cell proliferation or tumorigenesis. There are some
molecules that cooperate with ER through different mech-
anisms to promote tumor initiation and/or progression.
Although our unpublished data suggest that estrogen-ER
signaling does not induce ERRF and it is unknown
whether ERRF regulates ER, our functional experiments
revealed a necessary role of ERRF in the proliferation of
ER-positive breast cancer cells, as knockdown of ERRF
significantly impaired cell growth in vitro and tumorigen-
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suppression seems to be cell-cycle inhibition. These re-
sults, along with the significant correlation between ERRF
expression and ER and PR positivity, suggest that ERRF
is a novel ER-related factor that regulates the growth of
breast cancer cells. We noticed that some ER-negative
breast cancer cell lines also express higher levels of
ERRF (Figure 1A). We are currently testing whether ERRF
also plays a necessary role in the growth of these cells.
In ER-positive breast cancer, ER is expressed at
higher levels, and estrogen-ER signaling is necessary for
the proliferation of cancer cells.2,3 In normal luminal ep-
ithelial cells of the mammary gland, ER is also expressed,
although at lower levels, and estrogen-ER signaling is
necessary for the formation, maintenance, and homeo-
stasis of luminal epithelial cells.4 ER-positive mammary
epithelial cells do not seem to proliferate, although they
are often adjacent to proliferative epithelial cells in the
breast.5–8 Consistently, in cultured nontumorigenic yet
ER-positive breast epithelial cells, estrogen inhibits cell
proliferation.9–11 Taken together with our observations
that ERRF expression associates with ER and PR expres-
sion and that ERRF is required by ER-positive cells to
maintain proliferation, we hypothesize that ERRF plays a
role in the conversion of ER function from prodifferentia-
tion in the normal breast to proproliferation in breast can-
cer. We are currently testing this hypothesis in a series of
functional experiments.
The function of ERRF in normal tissues could be re-
lated to the hormonal regulation of cellular behavior
and/or function. In addition to the significant association
between ERRF expression and the expression of ER and
PR described in this study, all normal tissues that express
ERRF are hormone related and/or hormone producing,
including the brain, cortex, retina, and thyroid.22 For ex-
ample, retinal growth hormone is an antiapoptotic factor
in embryonic retinal ganglion cell differentiation.35 The
cancer tissues with detectable ERRF expression in the
SAGE database, ie, breast and prostate cancers, are
highly regulated by the hormones estrogen and andro-
gen, respectively. Assuming that ERRF is necessary for
hormones to induce the proliferation of normal cells, one
could speculate that the necessity of ERRF for the prolif-
eration of ER-positive breast cancer cells could reflect
ERRF’s function in normal cells: proproliferative yet con-
trolled and restricted, which could explain why patients
with higher ERRF expression survive better.
The selective ER modulator tamoxifen not only is the
most common endocrine agent used to treat all stages of
ER-positive breast cancer but also is effective in the
prevention of breast cancer in high-risk women.36 Mech-
anistically, tamoxifen interferes with estrogen-mediated
breast cancer growth by preventing estrogen from bind-
ing to ER. However, a substantial number of ER-positive
breast cancers fail to respond to tamoxifen therapy by de
novo or acquired resistance, which leads to disease pro-
gression and, ultimately, patient death.12,13 ER is still
maintained in most tamoxifen-resistant tumors and con-
tinues to regulate tumor growth.12 Therefore, identifica-
tion of ERRF as an ER-related factor that plays an impor-
tant role in the growth of ER-positive breast cancer couldprovide a new opportunity for developing and/or improv-
ing therapeutic intervention in ER-positive breast cancer,
especially for ER-positive but tamoxifen-resistant breast
cancer. ERRF expression seems to be quite restrictive in
normal tissues because so far it has been detected in
only the brain, cortex, retina, and thyroid among at least
25 different normal tissues examined by the SAGE ap-
proach,22 which could prove to be an advantage for
targeting ERRF in therapeutic development.
In summary, we found that whereas the mutation of
ERRF in breast cancer was rather infrequent (1 of 79 or
1.3%), the expression of ERRF was increased in breast
cancer, and the increase was significantly associated
with ER and PR expression in HER2-negative tumors.
ERRF expression inversely correlated with HER2 status.
Higher expression levels of ERRF in breast cancers were
also significantly associated with older age at diagnosis,
lower tumor grade, lower tumor stage, less lymph node
metastasis, and better patient survival. Functionally,
knockdown of ERRF in ER-positive breast cancer cell
lines dramatically suppressed cell proliferation in vitro
and in xenograft models. These results suggest that
ERRF plays a role in the proproliferative function of es-
trogen-ER signaling in the luminal A subtype of breast
cancer and that ERRF could be a potential therapeutic
target for breast cancer treatment.
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